Effect of adding bevacizumab to chemotherapy on pathologic response to preoperative systemic therapy of potentially resectable colorectal cancer liver metastases (CLM): A systematic review and meta-analysis.

Authors

Alexandre A. Jácome

Grupo Oncoclinicas, Belo Horizonte, Brazil

Alexandre A. Jácome , Fernanda A. Oliveira , Flora De Moraes Lino Silva , João Paulo da Silveira Nogueira Lima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.

First Author: Valerie Boige

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).

First Author: Nicholas Adam Bosma

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

Preliminary safety and efficacy of perioperative COI-B (capecitabine, oxaliplatin, irinotecan, and bevacizumab) in patients with borderline resectable or high–recurrence risk colorectal cancer liver metastases (CLM).

First Author: Marta Caporale

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of the Val d'Aurelle Center.

First Author: Emmanuelle Samalin